Bioanalysis and Biotransformation of Covalent Targeted Kinase Inhibitors in Oncology
- Universiteit Universiteit Utrecht
- Promovendus Irene Retmana
- Promoters Beijnen
- Co-Promoters ds Sparidans
- Jaar 2020 - 2024
The landscape of drug development as well as clinical practice has been changing over the last decennium, with the increasing availability and use of biobased therapies. This research is now focusing on the use and therapeutic drug monitoring of biobased factor VIII therapies in hemophilia A patients.
The aim of this project is to provide insight in the use of biologicals, including biosimilars, in clinical practice and add to the safe and effective use of these agents. We also provide guidance on the implementation of biosimilars in clinical practice from the perspective of different stakeholders including prescribers, pharmacists and patients.
Assessment of saliva/plasma ratio for drugs administered to (premature) neonates.
Therapeutic drug monitoring of clotting factor concentrates in patients Willebrand disease undergoing surgery.
Development of a webportal for TDM requests. Aplication of neural networks (deep learning) for population analysis.